K36 Therapeutics

Directions Website

K36 Therapeutics Targeting NSD2: Advancing Precision Medicine through Epigenetics

🧬Creating breakthrough therapies for the unmet medical needs of cancer patients worldwide.
🔬Our clinical trial is now open!

mCRPC is an abbreviation most people first meet on a lab report. Let's translate it. Metastatic castration-resistant pro...
10/16/2026

mCRPC is an abbreviation most people first meet on a lab report. Let's translate it. Metastatic castration-resistant prostate cancer means the cancer has spread and keeps growing despite therapies that lower testosterone.

Swipe for a plain-language breakdown, and save this for your next appointment. Knowledge empowers. Conversations improve care.

Behind every headline is a family.Yesterday, Pope Leo XIV's brother Louis Prevost shared that he's been living with mult...
10/15/2026

Behind every headline is a family.

Yesterday, Pope Leo XIV's brother Louis Prevost shared that he's been living with multiple myeloma since 2017. A stem cell transplant and a clinical trial in 2019 kept it quiet for years. A few months ago, it came back, and he's now in a new trial. So many families here know that rhythm. Remission, relapse, and figuring out what's next. His story is also a quiet reminder of what we talked about yesterday. Trials aren't a last resort. They're how care moves forward. Research keeps going.

We're thinking and 🙏 for Pope Leo XIV and his recent lung cancer diagnosis & his brother Louis Prevost, and their family, and every family facing cancer. Talk to your healthcare team. Link in bio.

“I wish I had known about myeloma sooner.” For those who recognize that feeling, sharing what you’ve learned can help s...
10/15/2026

“I wish I had known about myeloma sooner.” For those who recognize that feeling, sharing what you’ve learned can help someone else start asking questions.

Multiple myeloma is more than twice as common in Black people as in White people. Awareness belongs in our everyday conversations: around the dinner table, in our churches, community, and with the people we love.

At K36 Therapeutics, we’re helping keep that conversation going alongside patients, care partners, and advocates. Check out Health, Hope & Hip-Hop for an upcoming event in Chicago and International Myeloma Foundation Myeloma Awareness event in San Diego.

What is one thing you wish more people understood about myeloma? Share below, or share this post with someone who needs to know this cancer by name. 🧡

Let's clear up a few things about clinical trials. Often patients tell us they picture trials as a last resort, or worry...
10/14/2026

Let's clear up a few things about clinical trials. Often patients tell us they picture trials as a last resort, or worry they get a placebo instead of real treatment, or that joining meant they couldn't change their mind. The reality is different: trial study investigational approaches at many stages of a journey; placebos alone are rare in cancer research (investigational agent usually tested alongside standard care, not instead of it), and you can leave a trial at any time without affecting your regular care. We put together a short myth-vs-fact guide, including what actually happens, step by step: screening, consent, and participation.

Researchers are studying investigational medicines that target NSD2 in two trials now enrolling: K36-MMSET-001 for relapsed or refractory t(4;14) multiple myeloma (US, Canada, and Europe) and STRIKE-001 for metastatic prostate cancer (US). Ask your healthcare team whether a trial could be right for you - link in our bio.

K36 Therapeutics' Dr. Erin Flynt will be speaking at the International Workshop on High-Risk Multiple Myeloma in Charles...
10/13/2026

K36 Therapeutics' Dr. Erin Flynt will be speaking at the International Workshop on High-Risk Multiple Myeloma in Charleston, South Carolina, October 21–23, exchanging insights with researchers working to develop new treatment approaches.

Our investigational oral therapy, KTX-1001 (gintemetostat), targets NSD2/MMSET, a protein that is overactive in myeloma with a genetic change called t(4;14). A Phase 1 clinical trial is studying its safety and potential activity, both alone and in combination with other therapies.
Patients, families, and research teams make this work possible. We are grateful for their participation and the shared commitment to finding more options.

Interested in learning about the study? Visit our bio and ask your care team whether a clinical trial may be appropriate for you.

Have you ever brushed off exhaustion because life was busy?Our “Myeloma taught me” series highlights a message worth sha...
10/12/2026

Have you ever brushed off exhaustion because life was busy?

Our “Myeloma taught me” series highlights a message worth sharing: persistent, unexplained fatigue deserves attention.

Fatigue has many possible causes, and it can be a symptom of myeloma. If you’re feeling unusually tired and it isn’t going away, talk with your healthcare provider. Explain what has changed and how it’s affecting your day.

At K36 Therapeutics, we’re committed to helping more people recognize the signs of myeloma and feel comfortable speaking up about their health.

Share this with someone who could use a reminder to make time for themselves. 🧡

Myeloma Decoded. Your FISH report isn't written for you; let's translate it. FISH testing looks for genetic changes in y...
10/08/2026

Myeloma Decoded. Your FISH report isn't written for you; let's translate it. FISH testing looks for genetic changes in your MYELOMA Cells, and changes like t(4;14), del (17p) or 1q21+ can help your team understand your myeloma. Swipe through for a plain-language breakdown and save it for your next appointment. Knowledge empowers, conversations improve care Resources are available

Do you know your t(4;14) status? If you have relapsed or refractory multiple myeloma with the t(4;14) genetic translocat...
10/07/2026

Do you know your t(4;14) status? If you have relapsed or refractory multiple myeloma with the t(4;14) genetic translocation, a clinical trial may be an option. The K36-MMSET-001 study is enrolling in the US, Canada, and Europe. Ask your doctor if a trial could be right for you, click on our bio to learn more.

What do you know about your multiple myeloma? Each person's myeloma is unique. Tests such as cytogenetic testing, includ...
10/06/2026

What do you know about your multiple myeloma? Each person's myeloma is unique. Tests such as cytogenetic testing, including FISH testing, can help identify genetic changes in myeloma cells, including one called t(4;14).

Understanding whether your myeloma has t(4;14) may give you and your healthcare team a clearer picture of your disease and help you learn about clinical trials that could be right for you.

Ask about cytogenetic testing
Ask if your myeloma has t(4;14)
Ask whether a clinical trial may be an option for you

Did you know that multiple myeloma has a genetic fingerprint?Every person's myeloma is unique. Tests such as cytogenetic...
10/01/2026

Did you know that multiple myeloma has a genetic fingerprint?
Every person's myeloma is unique. Tests such as cytogenetic testing, including FISH testing, can help identify genetic changes in myeloma cells, including one called t(4;14). Understanding whether your myeloma has t(4;14) may give you and your healthcare team a clearer picture of your disease and help you learn about clinical trials that could be right for you.
💙 Ask about cytogenetic testing
💙 Ask if your myeloma has t(4;14)
💙 Ask whether a clinical trial may be an option for you

The more you know about your myeloma, the more empowered you can be in your care journey at k36tx.com

Address

1 Main Street 13Fl
Cambridge, MA
02142

Website

, ,

Alerts

Be the first to know and let us send you an email when K36 Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category